...
首页> 外文期刊>Medicine. >Definitive high-dose radiotherapy with concurrent chemotherapy for locally advanced rectal cancer: A case report and literature review
【24h】

Definitive high-dose radiotherapy with concurrent chemotherapy for locally advanced rectal cancer: A case report and literature review

机译:明确的大剂量放疗并发化疗治疗局部晚期直肠癌:一例病例报告并文献复习

获取原文
获取原文并翻译 | 示例

摘要

Background:Standard management for locally advanced rectal cancer (LARC) involves preoperative chemoradiotherapy (CRT) and radical surgery. However, this level of treatment may be unnecessary for a subgroup of LARC patients. Previous reports have shown that approximately 20% of LARC patients experience a complete tumor response to preoperative CRT. Post-CRT nonoperative management of these patients may prevent morbidities associated with radical surgery. To our knowledge, this case report firstly presents the favorable long-term outcomes of a LARC patient who underwent definitive aim CRT.Methods:The patient was 73 years' old, and staging workups revealed T3N2bM0 rectal adenocarcinoma. He agreed to receive CRT, but refused surgery. A radiotherapy (RT) dose of 64.8 Gy was prescribed, which was higher than conventional (50.4 Gy) preoperative aim RT. The regimen of concurrent chemotherapy was the same as that used in preoperative aim CRT: 2 cycles of 5-fluorouracil and leucovorin.Results:Three months after CRT completion, a complete tumor response was identified clinically. Colonoscopic biopsy after 1 year showed no tumor cells. This patient is alive after 4 years with no evidence of recurrence or severe toxicity.Conclusion:The long-term outcomes of this case indicate the feasibility of definitive high-dose RT with concurrent chemotherapy for LARC.
机译:背景:局部晚期直肠癌(LARC)的标准管理包括术前放化疗(CRT)和根治性手术。但是,对于LARC患者亚组来说,这种水平的治疗可能是不必要的。先前的报道表明,大约20%的LARC患者对术前CRT经历了完全的肿瘤反应。这些患者的CRT后非手术治疗可以预防与根治性手术相关的疾病。据我们所知,本病例报告首先介绍了接受明确目标CRT的LARC患者的长期远期结局。方法:该患者73岁,分期检查发现T3N2bM0直肠腺癌。他同意接受CRT,但拒绝接受手术。规定放疗(RT)剂量为64.8 Gy,高于常规术前目标RT(50.4 Gy)。同步化疗的方案与术前目标CRT方案相同:5-氟尿嘧啶和亚叶酸钙的2个周期。结果:CRT完成三个月后,在临床上确定了完整的肿瘤反应。 1年后的结肠镜活检未见肿瘤细胞。该患者在4年后还活着,没有复发或严重毒性的证据。结论:本例的长期预后表明了最终大剂量RT联合LARC化疗的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号